Compare BKU & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | ARQT |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2010 | 2020 |
| Metric | BKU | ARQT |
|---|---|---|
| Price | $46.72 | $26.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $51.09 | $29.29 |
| AVG Volume (30 Days) | 717.8K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-25-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | 14.61 | ★ 88.79 |
| EPS | ★ 3.53 | N/A |
| Revenue | $21,732,000.00 | ★ $376,072,000.00 |
| Revenue This Year | $16.55 | $26.91 |
| Revenue Next Year | $4.77 | $30.59 |
| P/E Ratio | $18.84 | ★ N/A |
| Revenue Growth | 7.45 | ★ 91.34 |
| 52 Week Low | $28.21 | $11.86 |
| 52 Week High | $52.11 | $31.77 |
| Indicator | BKU | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 49.35 |
| Support Level | $44.00 | $24.81 |
| Resistance Level | $46.92 | $27.26 |
| Average True Range (ATR) | 1.52 | 1.49 |
| MACD | -0.34 | 0.16 |
| Stochastic Oscillator | 13.50 | 46.95 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.